{"title":"Treatment of hypermenorrhea with mefenamic acid in women using IUDs.","authors":"N Pedron, M Lozano, R Aznar","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>49 women using either Lippes Loop D or copper T220C IUDs who were complaining of increased menstrual bleeding, were treated with mefenamic acid at a dosage of 500 mg 3 times/day for 5 days during their menstrual periods. Menstrual bleeding of each patient was quantified before initiation of the treatment and figures so obtained were used as pretreatment control values; during their 2nd cycle they received 1 placebo tablet 3 times/day for 5 days, the next 2 cycles utilized treatment with mefenamic acid, followed by a 5th cycle on placebo, and a 6th one without treatment. Of the 49 women admitted to the trial, 20 had pretreatment menstrual bleeding of more than 80 ml and 29 had less than 80 ml; groups 1 and 2, respectively. For group 1, a significant decrease in menstrual bleeding of 49.5% and 37.4% was observed during the 2 treatment cycles. Group 2, subjects with menstrual bleeding within the normal range, showed no decrease in menstrual bleeding.</p>","PeriodicalId":84493,"journal":{"name":"Contraceptive delivery systems","volume":"3 2","pages":"135-9"},"PeriodicalIF":0.0000,"publicationDate":"1982-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contraceptive delivery systems","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
49 women using either Lippes Loop D or copper T220C IUDs who were complaining of increased menstrual bleeding, were treated with mefenamic acid at a dosage of 500 mg 3 times/day for 5 days during their menstrual periods. Menstrual bleeding of each patient was quantified before initiation of the treatment and figures so obtained were used as pretreatment control values; during their 2nd cycle they received 1 placebo tablet 3 times/day for 5 days, the next 2 cycles utilized treatment with mefenamic acid, followed by a 5th cycle on placebo, and a 6th one without treatment. Of the 49 women admitted to the trial, 20 had pretreatment menstrual bleeding of more than 80 ml and 29 had less than 80 ml; groups 1 and 2, respectively. For group 1, a significant decrease in menstrual bleeding of 49.5% and 37.4% was observed during the 2 treatment cycles. Group 2, subjects with menstrual bleeding within the normal range, showed no decrease in menstrual bleeding.